Travere Therapeutics, Inc.

NASDAQ:TVTX

Biotechnology

Healthcare
$50.24 +1.20%

+$0.65 today

Market cap
$4.82B
Beta
1.14
P/E (TTM)
-235.0
EPS (TTM)
-$0.23
52W Low $13.97High $55.99

Volume 0.84M

Average 2.31M

TVTX Debt Repayment

Cash used to repay borrowings during the period.

Travere Therapeutics, Inc.NASDAQ: TVTX

Debt Repayment · Q3 FY2026 · quarter ended Sep 2026

Debt repayment turns positive

Q3 FY2026 debt repayment was $0, compared with -$68.9M a year earlier. Trailing-twelve-month debt repayment was $174.12M.

Context

  • Debt repayment amounted to 14.0% of revenue in FY2025, up 14.0 pp from a year earlier.
  • Debt repayment increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly debt repayment holds near $0 or moves back toward the trailing-twelve-month quarterly average of $43.53M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
-$68.9M— YoY
LTMSep 2026
$174.12M+352.7% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+100.0%——
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Debt Repayment history

USD · from the cash flow

Latest · FY2025
(68.9M) USD
Year-over-year change
—

Debt Repayment vs competitors

How TVTX compares with its peers on the latest reported figures

  • TVTX's LTM Sep 2026 debt repayment of $174.12M is the largest of the 5 companies compared; the peer median is $19.25M.
  • Its year-over-year change of +352.7% is the highest of 4, against a peer median of -67.9%.
  • Debt repayment amounts to 26.7% of revenue for TVTX, versus a peer median of 1.9%.
TVTX Competitors Peer median
Debt Repayment for TVTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TVTXTravere Therapeutics, Inc.LTM Sep 2026$174.12M +352.7%—26.7%
MLYSMineralys Therapeutics, Inc.LTM Jun 2026$96.49M ———
MAZEMaze Therapeutics, Inc.LTM Mar 2026$38.52M +342.0%—192.6%
PHARPharming Group N.V.LTM Mar 2026$1.07M -96.7%—0.3%
PROKProKidney Corp.LTM Mar 2026$17K -67.9%-6.7%1.9%
Peer median (excluding TVTX) $19.25M-67.9%-6.7%1.9%

Competitors are the stored peer set for TVTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(217.29M)(331.47M)(376.33M)(320.63M)(25.55M)
Depreciation & Amortization12.75M20.72M38.53M43.56M60.74M
Deferred Income Tax00000
Stock-Based Compensation29.57M38.14M44.25M36.91M44.87M
Change in Working Capital80.78M875K(25.48M)(63.02M)(14M)
Accounts Receivables17.95M(1.43M)(11.3M)(6.04M)(27.82M)
Inventory117K(1.21M)(39.42M)(3.77M)5.02M
Accounts Payables2.47M2.06M24.76M(17.56M)(85K)
Other Working Capital60.24M1.46M481K(35.64M)8.89M
Other Non-Cash Items79.41M85.44M39.01M65.71M(28.28M)
Operating Cash Flow(14.79M)(186.29M)(280.02M)(237.48M)37.78M
Capital Expenditures(24.15M)(28.37M)(41.59M)(101.21M)(58.16M)
Acquisitions (Net)00000
Purchases of Investments(547.08M)(385.39M)(443.94M)(125.76M)(237.14M)
Sales of Investments433.6M381.99M334.58M326.33M323.6M
Other Investing Activities(19.05M)(28.97M)165.81M(40K)(404K)
Investing Cash Flow(137.62M)(32.55M)55.78M99.33M27.89M
Debt Repayment0104.93M00(68.9M)
Common Stock Issued224.93M19.55M191.2M134.74M37.54M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities6.75M(6.9M)27.55M4.68M(2.1M)
Financing Cash Flow231.68M117.57M218.75M139.42M(33.47M)
Effect of Forex Changes1.71M(2.79M)1.98M(913K)2.29M
Net Change in Cash80.98M(104.07M)(3.51M)359K34.5M
Free Cash Flow(38.94M)(214.66M)(321.61M)(338.69M)(20.37M)

Travere Therapeutics, Inc.

NASDAQ:TVTX

Intrinsic Alpha fair value

Locked

Current Price

$50.24

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.